SUNNYVALE, Calif.--(BUSINESS WIRE)--Oct 17, 2012--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will release three-year clinical follow-up data on its CE Mark-approved DESyne ® Novolimus Eluting Coronary Stent System, and one year clinical and MSCT (Multi Slice Computed Tomography) results for its fully bioresorbable drug-eluting scaffold system, the DESolve™ Bioresorbable Coronary Scaffold, at the 24 th annual Transcatheter Cardiovascular Technologies Conference in Miami on Tuesday, October 23.
Elixir will also announce new data on its other drug eluting stent platforms during the conference. Following are the details of Elixir Medical’s programs and activities at TCT in Eastern Standard Time (EST): Tuesday, Oct. 23: 12 – 12:10 pm, Miami Beach Convention Center, Room C221/222 Session: Bioresorbable Vascular Scaffolds 6-Month Angiographic Follow-up of the Novel DESolve™ Myolimus-Eluting Bioresorbable Coronary Scaffold for the Treatment of Non-Complex Coronary Lesions – Results from the DESolve I First-In-Man Trial • Ricardo Costa, MD, PhD, Institute of Dante Pazzanese de Cardiologia in Sao Paulo, Brazil 1:35 - 1:45 pm, Miami Beach Convention Center, Room B217/218 Session: First in Human Studies: Global Regulatory and Translational Considerations Evaluation of the Myolimus-Eluting Bioresorbable Coronary Scaffold: 6-Month Clinical and Imaging Results • Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium 2:44 – 2:50 pm, Miami Beach Convention Center, Hall A – Coronary Theater Session II: Metallic Drug-Eluting Stents with Bioabsorbable Polymers DESyne BD – Program update • Ricardo Costa, MD, PhD, Institute of Dante Pazzanese de Cardiologia in Sao Paulo, Brazil 5:22 - 5:32 pm, Miami Beach Convention Center, Hall A – Coronary Theater Session: Next-Generation DES and Bioabsorbable Scaffolds First-in-Man Results with a Myolimus-Eluting Bioresorbable PLLA-based Vascular Scaffold (Elixir DESolve) • Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium 6:30 – 8:30 pm, Loews Miami Beach Hotel, Americana Ballroom, Salon 4 1601 Collins Ave., Miami Beach, FL 33130 Vascular Restoration The Bioresorbable DESolve Scaffold Platform Agenda • Reception • Elixir Medical Program Overview • DESyne Clinical Data - EXCELLA II 3-year follow-up data of the DESyne Novolimus Eluting Coronary Stent System • DESyne BD Clinical Data • DESolve Scaffold Clinical Data - One Year Follow-Up Results of the DESolve Bioresorbable Coronary Scaffold System • Discussion and Closing Remarks Chairman Martin B. Leon, MD, New York – Presbyterian Hospital / Columbia University Medical Center, New York, NY, USA Faculty • John Ormiston, MBChB, Mercy Angiographic Unit, Auckland, New Zealand • Joachim Schofer, MD, Universitares Herz- und GefaBzentrum, Hamburg, Germany • Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium • Bernhard Witzenbichler, MD, Charite – Campus Benjamin Franklin, Berlin, Germany Space is limited: Please register in advance at www.tctconference.com/satelliteprograms Wednesday, Oct. 24: 1:45 pm, Miami Beach Convention Center, Main Arena LIVE CASE from Sao Paulo, Brazil DESolve Nx 6-month Angiographic, IVUS and OCT follow-up • Professor Alexandre Abizaid, M.D., Ph.D., of the Institute of Dante Pazzanese de Cardiologia in Sao Paulo, Brazil Elixir Medical will have a booth at TCT: Booth 929, Exhibit Hall. The booth will be open Tuesday, October 23 rd, 12:00 pm to 5:00 pm, and Wednesday through Thursday, October 25 th – 26 th from 9:00 am to 5:00 pm.
About Elixir Medical Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.comCONTACT: Elixir Medical Vinayak Bhat, Ph.D., 408-636-2006 KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA FLORIDA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL SOURCE: Elixir Medical Corporation Copyright Business Wire 2012 PUB: 10/17/2012 07:00 AM/DISC: 10/17/2012 07:00 AM http://www.businesswire.com/news/home/20121017005748/